A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
- Status
- COMPLETED
- Phase
- PHASE1
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)
- Status
- UNKNOWN
- Phase
- PHASE2
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Cetuximab in Head and Neck Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
- Status
- UNKNOWN
- Phase
- PHASE2
Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE1